Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06313086 | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 442 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06341621 | Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib(Rainbow) | recruiting | Phase 3 | 1,900 | Fudan UniversityOTHER | 1 | Apr 10, 2024 |
| clinicaltrials |
| NCT06313463 | Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy | recruiting | Phase 3 | 375 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06268652 | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | recruiting | Phase 3 | 302 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05891093 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | recruiting | Phase 3 | 766 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | recruiting | Phase 3 | 372 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04722692 | Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ(SENTINOT_2) | recruiting | Phase 3 | 500 | Uppsala UniversityOTHER | 3 | Aug 3, 2023 | clinicaltrials |
| NCT05430399 | Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 3 | 349 | Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05904964 | Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) | recruiting | Phase 3 | 288 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05851014 | A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | recruiting | Phase 3 | 350 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT05212454 | Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks | recruiting | Phase 3 | 400 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05804916 | Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer | recruiting | Phase 2 / Phase 3 | 556 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04803539 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC(Artemis) | recruiting | Phase 2 / Phase 3 | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03150576 | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer(PARTNER) | recruiting | Phase 2 / Phase 3 | 780 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT04263298 | Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer | recruiting | Phase 3 | 210 | Herui YaoOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03829553 | Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment(HARVEST) | recruiting | Phase 3 | 801 | Ruijin HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04079049 | BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases(BreCLIM-2) | recruiting | Phase 3 | 200 | Umeå UniversityOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT02535221 | Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer | recruiting | Phase 3 | 234 | Peking UniversityOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05059379 | Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer(SUCLANODE) | recruiting | Phase 3 | 1,650 | Fudan UniversityOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04137653 | Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT | recruiting | Phase 3 | 1,498 | Shengjing HospitalOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04646759 | Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer | recruiting | Phase 3 | 516 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT03561740 | A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients(SMART) | recruiting | Phase 3 | 794 | Sun Yat-sen UniversityOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01185132 | Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy(2009-APBI) | recruiting | Phase 3 | 660 | Rocky Mountain Cancer CentersOTHER | 1 | Jun 26, 2014 | clinicaltrials |
Data updated 23 days agoSource updated May 10, 2024source: clinicaltrials